Kenvue faces declining sales and high debt post-spin-off. Read why a dividend cut may be imminent and why KVUE stock is a ...

Texas AG Ken Paxton has sued Johnson & Johnson and Kenvue, alleging they hid Tylenol’s pregnancy risks despite no proven ...

Texas Attorney General Ken Paxton claims the makers of Tylenol failed to warn consumers of the risks. Here's who makes ...

The consumer healthcare company currently trades at about 15x earnings multiple, which represents a 9.41% undervaluation ...

As the consumer health company battles claims from the Trump administration that its painkiller Tylenol is linked to autism, Kenvue will bring on Halvorson as its next marketing chief.

Texas Attorney General Ken Paxton is suing the makers of Tylenol over allegedly deceptively marketing the over-the-counter ...

NRG Therapeutics made three senior appointments in newly created roles: Sarah Almond as VP of translational biology; David Brocklebank as director of clinical operations and Kathryn Oliver as director ...

After popular pain med Tylenol came under fire from officials in the Trump administration for an alleged link to autism if ...

Kenvue Inc. (NYSE: KVUE) will announce its third quarter 2025 financial results before the market opens on November 6, 2025.

Kenvue (NYSE:KVUE), the consumer healthcare spin-off from Johnson & Johnson, has experienced a significant decline in its ...